At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 19 enrolled
Drug / intervention
Evolocumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Evolocumab on Coronary Endothelial Function
In Brief
A Phase 2 clinical trial evaluating Evolocumab for Human Immunodeficiency Virus and Coronary Artery Disease. Completed, enrolled 19 participants across 1 site.
Detailed Summary
The investigators propose a pilot study using (1) MRI to assess coronary artery endothelial function, (2) brachial ultrasound to assess systemic endothelial function, (3) serum markers of inflammation and of endothelial cell function and (4) echocardiographic measures of left ventricular diastolic and systolic properties, before and following initiation of PCSK9 antibody in HIV positive subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsAmerican Heart Association
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedApr 2018
Enrollment StartMay 2018
Primary CompletionNov 2019
TodayJul 2026
First PostedApr 18, 2018
Enrollment StartMay 4, 2018
Primary CompletionNov 30, 2019
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 8.2 years ago
Interventions
Evolocumabdrug
Evolocumab sq once a month for a total of two doses